IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 198 participants.

Also called NCT07473960

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 198 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT07473960
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT07473960. Randomized; single masking; primary purpose treatment. Start 2026-04-01 (actual); primary completion 2026-08-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
Condition
Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
Intervention (Drug)
IBI306
Intervention (Drug)
placebo
Intervention (Drug)
placebo
Intervention (Drug)
IBI306
Lead sponsor
Innovent Biologics (Suzhou) Co. Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07473960
Content hash
cbd9d58d857b003b59b48e1de3ee2f4b1a473c01d91a0834860d36de25e2a61f